Improving Tablet Quality with Compression to Equal Force Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving Tablet Quality with Compression to Equal Force Technology
Traditional tablet presses do not measure tablets' tensile strength, yet this characteristic strongly influences tablet quality. The author describes a compression technique that accounts for tensile strength and produces tablets with consistent weight and disintegration time.


Pharmaceutical Technology


The effect of equal porosity on tablet properties

The author performed an experiment using an ibuprofen 85 DC formulation with 0.5% magnesium stearate. The tabletting was done on the "MODUL P" tablet press (GEA Courtoy, Halle, Belgium). This press is equipped with the air compensator at precompression and main compression.

The advantage of equal porosity tableting is the reduction of variability in density, tensile strength, and disintegration.

Compression to EF. For the above formulation, a series of tablets was compressed at a constant force of 650 daN with a nominal tablet weight of 233 mg.

Tablets were compressed within ± 4% of their nominal weight. All tablets were compressed to the same peak compression force.

Compression to ET. The same series of tablets was compressed to ET. The distance between the two rollers remained constant throughout compression.

Results


Figure 5
Figures 5–8 show the analysis. The weight variation demonstrates an increase of force when the machine uses the ET mode and tablet weights increase.


Figure 6
The influence of tablet weight on density for ET and EF. Density increases as tablet weight increases. Density decreases when tablet weight decreases. The variability of the density during compression to EF is 1.1%. The variability of the density during compression to ET is 8%. Both tests used the same series of tablets within the same weight range.


Figure 7
Testing the tablets for tensile strength. The variability in tensile strength was more significant than that of density. Tablets compressed to EF showed as little as 1.2% variation. Tablets compressed to ET showed as much as 29.6% variation.


Figure 8
Testing the tablets for disintegration time. Disintegration time varied widely according to the compression technique. Tablets compressed to EF showed only 14.5% variability in disintegration time. Tablets compressed to ET, however, showed more than 105% variability in disintegration time.

Conclusion

The data were gathered under controlled conditions for ibuprofen 85 DC, and tablets were compressed within the US Pharmacopoeia's weight-variation limits.

Tablets compressed under equal force (EF) showed a much more consistent density, tensile strength, and disintegration rate than tablets compressed to equal thickness.

Different results might be expected from other drug formulations, but these data clearly indicate the advantage of a rotary press with EF capability.

Machines with both capabilities, therefore, give formulation and production departments great scope for improving tablet quality.

Johan Van Evelghem is a product and compression-technology manager at Courtoy, 9165 Rumsey Rd., Columbia, MD 21045, tel., 410.997.6692,

Reference

1. K.A. Khan and C.T. Rhodes, "Effect of Variation in Compaction Force on Properties of Six Direct Compression Tablet Formulations," J. Pharm. Sci. 65 (12), 1835–1837 (1976).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here